Justin Hou Ming Yung

Mr. Justin Hou Ming Yung

University of Toronto
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Cells
Verified
Journal Article
Open access
PDF file
Justin Hou Ming YungJustin Hou Ming Yung
Justin Hou Ming Yung
Adria GiaccaAdria Giacca
Adria Giacca
Obesity has been described as a global epidemic and is a low-grade chronic inflammatory disease that arises as a consequence of energy imbalance. Obesity increases the risk of type 2 diabetes (T2D), by mechanisms that are not entirely clarified. Elevated circulating pro-inflammatory cytokines and free fatty acids (FFA) during obesity cause insulin resistance and ß-cell dysfunction, the two main features of T2D, which are both aggravated with the progressive development of hyperglycemia. The inflammatory kinase c-jun N-terminal kinase (JNK) responds to various cellular stress signals activated by cytokines, free fatty acids and hyperglycemia, and is a key mediator in the transition between obesity and T2D. Specifically, JNK mediates both insulin resistance and ß-cell dysfunction, and is therefore a potential target for T2D therapy.

29 March 2024 in Endocrinology
Verified
Journal Article
Open access
PDF file
AIAleksandar Ivovic
Aleksandar Ivovic
Justin Hou Ming YungJustin Hou Ming Yung
Justin Hou Ming Yung
AOAndrei I Oprescu
Andrei I Oprescu
FVFilip Vlavcheski
Filip Vlavcheski
YMYusaku Mori
Yusaku Mori
Adria GiaccaAdria Giacca
Adria Giacca
In the classical insulin target tissues of liver, muscle, and adipose tissue, chronically elevated levels of free fatty acids (FFA) impair insulin signaling. Insulin signaling molecules are also present in β-cells where they play a role in β-cell function. Therefore, inhibition of the insulin/insulin-like growth factor 1 pathway may be involved in fat-induced β-cell dysfunction. To address the role of β-cell insulin resistance in FFA-induced β-cell dysfunction we co-infused bisperoxovanadate (BPV) with oleate or olive oil for 48 hours in rats. BPV, a tyrosine phosphatase inhibitor, acts as an insulin mimetic and is devoid of any antioxidant effect that could prevent β-cell dysfunction, unlike most insulin sensitizers. Following fat infusion, rats either underwent hyperglycemic clamps for assessment of β-cell function in vivo or islets were isolated for ex vivo assessment of glucose-stimulated insulin secretion (GSIS). We also incubated islets with oleate or palmitate and BPV for in vitro assessment of GSIS and Akt (protein kinase B) phosphorylation. Next, mice with β-cell specific deletion of PTEN (phosphatase and tensin homolog; negative regulator of insulin signaling) and littermate controls were infused with oleate for 48 hours, followed by hyperglycemic clamps or ex vivo evaluation of GSIS. In rat experiments, BPV protected against fat-induced impairment of β-cell function in vivo, ex vivo, and in vitro. In mice, β-cell specific deletion of PTEN protected against oleate-induced β-cell dysfunction in vivo and ex vivo. These data support the hypothesis that β-cell insulin resistance plays a causal role in FFA-induced β-cell dysfunction.

4 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
Justin Hou Ming YungJustin Hou Ming Yung
Justin Hou Ming Yung
LYLucy Shu Nga Yeung
Lucy Shu Nga Yeung
AIAleksandar Ivovic
Aleksandar Ivovic
YTYao Fang Tan
Yao Fang Tan
EJEmelien Mariella Jentz
Emelien Mariella Jentz
MMMortimer Mamelak
Mortimer Mamelak
Oxidative stress caused by the exposure of pancreatic ß-cells to high levels of fatty acids impairs insulin secretion. This lipotoxicity is thought to play an important role in ß-cell failure in type 2 diabetes and can be prevented by antioxidants. Gamma-hydroxybutyrate (GHB), an endogenous antioxidant and energy source, has previously been shown to protect mice from streptozotocin and alloxan-induced diabetes; both compounds are generators of oxidative stress and yield models of type-1 diabetes. We sought to determine whether GHB could protect mouse islets from lipotoxicity caused by palmitate, a model relevant to type 2 diabetes. We found that GHB prevented the generation of palmitate-induced reactive oxygen species and the associated lipotoxic inhibition of glucose-stimulated insulin secretion while increasing the NADPH/NADP+ ratio. GHB may owe its antioxidant and insulin secretory effects to the formation of NADPH.

22 September 2026 in Diabetes
Verified
Journal Article
Closed access
Justin Hou Ming YungJustin Hou Ming Yung
Justin Hou Ming Yung
EHEmily G. Hoffman
Emily G. Hoffman
AIAleksandar Ivovic
Aleksandar Ivovic
SRS.M. Niazur Rahman
S.M. Niazur Rahman
TDTejas Desai
Tejas Desai
KPKacey J. Prentice
Kacey J. Prentice
The intracellular nucleotide-binding oligomerization domain (Nod) receptors of innate immunity have been demonstrated to play a significant role in metabolism. Saturated fatty acids have been reported to directly activate Nods, and deletion of Nod1 protects against glucose intolerance induced by a high-fat diet. This suggests a role for Nod1 in β-cells because glucose tolerance is heavily determined by β-cell performance. Therefore, we hypothesized that saturated fatty acid–induced β-cell dysfunction is mediated in part by Nod1 in the β-cell. Both mouse and human islets express Nod1 mRNA. Treatment with the Nod1 ligands C12 iE-DAP and FK565 decreased β-cell function in vitro and in vivo, respectively, in male mice. Mechanistically, this was mediated by JNK and IKKβ activation, because islets from JNK1-knockout (KO) and β-cell–specific IKKβ-KO mice were protected against Nod1 ligand–induced dysfunction. In vitro, islets of Nod1-KO mice were protected from palmitate-induced β-cell dysfunction. Similarly, in vivo, whole-body or β-cell–specific Nod1-KO mice were protected from palmitate-induced β-cell dysfunction during hyperglycemic clamps. Together, these data demonstrate that Nod1 plays a causal role in saturated fatty acid–induced β-cell dysfunction in vitro and in vivo in male mice. Article Highlights: The innate immunity receptor nucleotide-binding oligomerization domain 1 (Nod1) can be activated by saturated fatty acids and is implicated in high-fat diet-induced inflammation and insulin resistance. This implies Nod1 plays a role in glucose homeostasis; therefore, we sought to determine whether saturated fatty acids cause pancreatic β-cell dysfunction through Nod1. Our data demonstrate that Nod1 is involved in palmitate-induced β-cell dysfunction in vitro and in vivo.

1 June 2019 in Diabetes
Verified
Journal Article
Closed access
Justin Hou Ming YungJustin Hou Ming Yung
Justin Hou Ming Yung
LYLucy Shu Nga Yeung
Lucy Shu Nga Yeung
ANAshraf Nahle
Ashraf Nahle
KKKhajag Koulajian
Khajag Koulajian
AGAdria Giacca
Adria Giacca
In obesity, chronically elevated circulating free fatty acids (FFA) potentially cause ß-cell dysfunction which leads to type 2 diabetes (T2D). In vitro data have identified various cellular mechanisms leading to FFA-induced ß-cell dysfunction including activation of inflammatory kinase c-Jun N-terminal kinase (JNK). In the ß-cell, JNK1 responds to oxidative stress or ER stress, which can both be caused by FFA. Previous in vitro studies from our group have demonstrated that islets of JNK1-null mice are protected from the effect of palmitate but not oleate on inducing ß-cell dysfunction, suggesting that activation of JNK1 is specific to saturated FFA. Thus, we hypothesized that saturated FFA-induced ß-cell dysfunction is mediated in part by JNK. Due to its detergent effects, palmitate cannot be infused directly into circulation. Thus, ethylpalmitate was used, as the ethyl group reduces the toxic effect. Mice can hydrolyze the ethyl group in circulation, producing palmitate and ethanol. JNK1-null (KO) mice and their littermate controls (WT) were infused with ethylpalmitate or ethanol vehicle for 48 hours, after which their pancreatic islets were isolated for ex vivo determination of insulin secretion. We confirmed that ethylpalmitate infusion does significantly increase plasma FFA as compared to vehicle infusion. We found that WT mice infused with ethylpalmitate demonstrated significantly decreased insulin secretion as compared with WT mice infused with vehicle, whereas JNK1-null mice infused with ethylpalmitate had similar insulin secretion as controls. These data suggest that JNK1 plays a causal role in saturated FFA-induced ß-cell dysfunction in vivo. Disclosure: J. Yung: None. L. Yeung: None. A. Nahle: None. K. Koulajian: None. A. Giacca: Research Support; Self; Jazz Pharmaceuticals. Funding: Canadian Institutes of Health Research

1 June 2021 in Diabetes
Verified
Journal Article
Closed access
Justin Hou Ming YungJustin Hou Ming Yung
Justin Hou Ming Yung
AIAleksandar Ivovic
Aleksandar Ivovic
ICIsabel Clark
Isabel Clark
FLFiona Li
Fiona Li
BLBrian Lin
Brian Lin
AGAdria Giacca
Adria Giacca
Chronic elevation of free fatty acids (FFA) in obesity may cause ß-cell dysfunction leading to type 2 diabetes (T2D). Recent studies have focused on innate immunity receptors due to evidence implicating inflammation in obesity-induced T2D. While several of these receptors have been implicated in FFA-induced ß-cell dysfunction, the nucleotide-binding oligomerization domain (NOD) receptors have not been investigated. Our previous work showed that whole-body NOD1-null mice were protected from palmitate-induced ß-cell dysfunction in vivo. This may be due to lack of NOD1 in ß-cells and/or macrophages infiltrating islets. Also, islets of whole-body NOD1-null and JNK1-null mice were protected from ß-cell dysfunction induced by palmitate but not oleate in vitro, suggesting NOD1 activation is likely in ß-cells, is specific to saturated FFA and may cause ß-cell dysfunction via JNK1. Thus, we hypothesized that ß-cell NOD1 mediates palmitate-induced ß-cell dysfunction in vivo, and that JNK1 is downstream of NOD1 activation. Addition of an ethyl group on palmitate reduces toxicity of unbound palmitate, thus ethylpalmitate (EtPAL) was used. Ethyl esterases in mouse plasma hydrolyze EtPAL into palmitate and ethanol. ß-cell specific NOD1-null (ßKO) mice (using Ins1- and RIP-Cre) and their controls were infused with EtPAL or ethanol vehicle (Veh) for 48 hours, followed by a hyperglycemic clamp to evaluate ß-cell function in vivo from the disposition index (DI). Islets of JNK1-null and wildtype (WT) mice were isolated and treated with a NOD1 activator to investigate the NOD1-JNK1 axis. As expected, EtPAL infusion elevated plasma FFA. EtPAL decreased DI in control mice, while EtPAL-infused ßKO mice had similar DI to Veh-infused mice. Further, the NOD1 activator reduced insulin secretion in WT islets but not in JNK1-null islets. These data implicate ß-cell NOD1-JNK1 axis in palmitate-induced ß-cell dysfunction and reveal a novel pathway that could be targeted for manipulation in order to preserve ß-cell function. Disclosure: J. Yung: None. A. Ivovic: None. I. Clark: None. F. Li: None. B. Lin: None. Y. Tan: None. A. Giacca: None. Funding: Canadian Institutes of Health Research (CIHR50748)